StockNews.AI
SF
StockNews.AI
4 hrs

Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation Forum

1. Recludix Pharma will present at the Stifel Immunology Forum on Sept 16, 2025. 2. They are developing STAT6 inhibitors for inflammatory diseases like asthma and arthritis. 3. Recludix has a collaboration with Sanofi for STAT6 inhibitor development. 4. The company utilizes an advanced drug discovery platform for drug development. 5. Recludix was recognized as a 2024 Fierce 15 biotech company.

4m saved
Insight
Article

FAQ

Why Bullish?

The announcement of collaborations and advancements in drug development often positively influences stock performance, similar to spikes seen with drug trial successes in related companies.

How important is it?

The collaboration with Sanofi and advancements in drug development indicate strong future growth potential, relevant for investors in SF.

Why Long Term?

The development of new drugs takes time; the potential market success could enhance SF's valuation in the long-term, as seen with biotech stock rallies following FDA approvals.

Related Companies

SNYBMYNVAX
September 11, 2025 16:00 ET  | Source: Recludix Pharma, Inc. SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., president and chief executive officer, Ajay Nirula, M.D., Ph.D., executive vice president and head of research and development, and Brian Hodous, Ph.D., chief scientific officer, will participate in the Stifel 2025 Virtual Immunology and Inflammation Forum. An overview of the company will be presented on Tuesday, September 16, 2025 at 3:00 p.m. Eastern Time. To access the live and archived webcast, visit the News & Events page of the company’s website at https://recludixpharma.com/news-events. The archived webcast will be available for 30 days following the presentation. About RecludixRecludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced program is focused on STAT6 (signal transducer and activator of transcription 6) where abnormal activation is found in inflammatory diseases, such as atopic dermatitis, asthma, rheumatoid arthritis and chronic spontaneous urticaria. The company has a strategic collaboration with Sanofi for the development and commercialization of a STAT6 inhibitor, and it is planning to submit an Investigational New Drug application for its STAT6 inhibitor REX-8756 in 2025. Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional programs. Recludix was named a 2024 Fierce 15 biotech company. For more information, please visit the company’s website at https://recludixpharma.com. Recludix ContactsMatt Caldemeyer Chief Business Officermcaldemeyer@recludix.comAlexandra Santos asantos@wheelhouselsa.com Aljanae Reynoldsareynolds@wheelhouselsa.com

Related News